CKPT vs. EQ, RPHM, KZR, TLSA, ELDN, IMMX, ANEB, CALC, BLRX, and KRON
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Equillium (EQ), Reneo Pharmaceuticals (RPHM), Kezar Life Sciences (KZR), Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), Immix Biopharma (IMMX), Anebulo Pharmaceuticals (ANEB), CalciMedica (CALC), BioLineRx (BLRX), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.
In the previous week, Checkpoint Therapeutics had 9 more articles in the media than Equillium. MarketBeat recorded 14 mentions for Checkpoint Therapeutics and 5 mentions for Equillium. Equillium's average media sentiment score of 0.90 beat Checkpoint Therapeutics' score of 0.47 indicating that Equillium is being referred to more favorably in the news media.
Equillium has a net margin of -32.01% compared to Checkpoint Therapeutics' net margin of -50,336.89%. Checkpoint Therapeutics' return on equity of 0.00% beat Equillium's return on equity.
Checkpoint Therapeutics presently has a consensus target price of $22.60, indicating a potential upside of 1,102.13%. Equillium has a consensus target price of $3.90, indicating a potential upside of 150.00%. Given Checkpoint Therapeutics' higher possible upside, analysts plainly believe Checkpoint Therapeutics is more favorable than Equillium.
Equillium has higher revenue and earnings than Checkpoint Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
Checkpoint Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Equillium has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
Checkpoint Therapeutics received 137 more outperform votes than Equillium when rated by MarketBeat users. However, 82.93% of users gave Equillium an outperform vote while only 66.28% of users gave Checkpoint Therapeutics an outperform vote.
22.0% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Comparatively, 30.3% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Equillium beats Checkpoint Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
